Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.
| Website: | www.rexahn.com |
| Email: | info@rexahn.com |
| Main Phone: | +1 240 268-5300 |
| Address: | 15245 Shady Grove Road |
| Address 2: | Suite 455 |
| State: | MD |
| City / Town: | Rockville |
| Country: | USA |
| Postal Code: | 20850 |
| Exchange: | AMX |
| CEO: | Douglas J. Swirsky |
| Employees: | 10 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview
Shares of Rexahn Pharmaceuticals (RNN) continued to show considerable volatility on Tuesday and Wednesday, making a late run to end Tuesday’s trading session then swinging from positive to
Shares in late-stage biopharmaceutical company Rexahn Pharmaceuticals (RNN) experienced a wildly volatile day in Monday in action clearly connected to a presentation by CEO Peter Suzdak, PhD, on
Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they
Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a
From bottom to top in 2013, shares of Rexahn Pharmaceuticals (RNN) had more than doubled when it peaked at 66 cents in July, fueled in part by optimism of an Investigational New Drug application
In this week's interview with Francis Gaskins, Equities.com discusses some of the best recent performers and takes a look at what set them apart from the laggers. Gaskins also sheds some light on
U.S. stocks continued higher on Wednesday with the Dow Jones Industrial Average trading as high as 12,284. The NASDAQ traded as high as 2747 on Wednesday. U.S. stocks continued a strong rebound on
Apologies in advance to everybody that does not follow football- but understanding the quarterback rankings- and comparing it to trading and investing can be very enlightening in many ways.First,
It seems like only a few years ago that American automakers like General Motors Company (NYSE: GM), Ford Motor Company (NYSE: F) and Chrysler were all in dire straits. The Big Three were all
Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.
| Website: | www.rexahn.com |
| Email: | info@rexahn.com |
| Main Phone: | +1 240 268-5300 |
| Address: | 15245 Shady Grove Road |
| Address 2: | Suite 455 |
| State: | MD |
| City / Town: | Rockville |
| Country: | USA |
| Postal Code: | 20850 |
| Exchange: | AMX |
| CEO: | Douglas J. Swirsky |
| Employees: | 10 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview
Shares of Rexahn Pharmaceuticals (RNN) continued to show considerable volatility on Tuesday and Wednesday, making a late run to end Tuesday’s trading session then swinging from positive to
Shares in late-stage biopharmaceutical company Rexahn Pharmaceuticals (RNN) experienced a wildly volatile day in Monday in action clearly connected to a presentation by CEO Peter Suzdak, PhD, on
Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they
Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a
From bottom to top in 2013, shares of Rexahn Pharmaceuticals (RNN) had more than doubled when it peaked at 66 cents in July, fueled in part by optimism of an Investigational New Drug application
In this week's interview with Francis Gaskins, Equities.com discusses some of the best recent performers and takes a look at what set them apart from the laggers. Gaskins also sheds some light on
U.S. stocks continued higher on Wednesday with the Dow Jones Industrial Average trading as high as 12,284. The NASDAQ traded as high as 2747 on Wednesday. U.S. stocks continued a strong rebound on
Apologies in advance to everybody that does not follow football- but understanding the quarterback rankings- and comparing it to trading and investing can be very enlightening in many ways.First,
It seems like only a few years ago that American automakers like General Motors Company (NYSE: GM), Ford Motor Company (NYSE: F) and Chrysler were all in dire straits. The Big Three were all
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 4 |
| Number of Buys | 0 | 4 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 20250 |
| Last 10 Buys | Shares |
|---|---|
| Richard Kivel | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Peter C. Brandt | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Chang Ho Ahn | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Chang Ho Ahn | 1,000 |
| Tae Heum Jeong | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 19.5 | 19.5 | 19.5 | 19.5 |
| Low Target Price Estimate | 13 | 13 | 13 | 13 |
| Mean Target Price Estimate | 16.25 | 16.25 | 16.25 | 16.25 |
| Standard Deviation | 4.6 | 4.6 | 4.6 | 4.6 |
| Date of Most Recent Estimate | 03/12/18 | 03/12/18 | 03/12/18 | 03/12/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive | 4 | 2018-06-14 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 40 | 2018-05-04 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 46 | 2018-04-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-18 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 46 | 2018-04-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-09 |
| 10-K | Annual report with a comprehensive overview of the company | 119 | 2018-03-09 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-02 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.33 | 1.33 | 1.33 | 1.33 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait